Earnings ·
Cullinan Therapeutics reports $49.4M Q3 loss, holds $313.8M cash with runway into 2029
CGEMCullinan Therapeutics, Inc.
Cullinan Therapeutics reported a net loss of $49.4 million for the third quarter ended September 30, 2026, compared to a $50.6 million loss in the prior-year period. Research and development expenses decreased to $40.2 million from $42.0 million, while general and administrative costs fell to $12.4 million from $13.6 million. The company ended the quarter with $313.8 million in cash and investments, projecting a financial runway into 2029 under its current operating plan. Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing T cell engagers for autoimmune diseases and cancer.